NZ582056A - Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation - Google Patents

Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation

Info

Publication number
NZ582056A
NZ582056A NZ582056A NZ58205608A NZ582056A NZ 582056 A NZ582056 A NZ 582056A NZ 582056 A NZ582056 A NZ 582056A NZ 58205608 A NZ58205608 A NZ 58205608A NZ 582056 A NZ582056 A NZ 582056A
Authority
NZ
New Zealand
Prior art keywords
carboxamide
indole
compounds
pyrimidin
formula
Prior art date
Application number
NZ582056A
Other languages
English (en)
Inventor
Rajagopal Bakthavatchalam
David C Ihle
Scott M Capitosti
David J Wustrow
Jun Yuan
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NZ582056A publication Critical patent/NZ582056A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ582056A 2007-08-10 2008-08-11 Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation NZ582056A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10
PCT/US2008/072760 WO2009023623A1 (en) 2007-08-10 2008-08-11 Heteroaryl amide analogues

Publications (1)

Publication Number Publication Date
NZ582056A true NZ582056A (en) 2012-08-31

Family

ID=40351102

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ582056A NZ582056A (en) 2007-08-10 2008-08-11 Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation

Country Status (14)

Country Link
EP (1) EP2185560A4 (enExample)
JP (2) JP2010535816A (enExample)
KR (1) KR20100066422A (enExample)
CN (1) CN101778850A (enExample)
AU (1) AU2008286946B2 (enExample)
BR (1) BRPI0812594A2 (enExample)
CA (1) CA2691512A1 (enExample)
CO (1) CO6251319A2 (enExample)
EA (1) EA020332B1 (enExample)
IL (1) IL202550A0 (enExample)
NZ (1) NZ582056A (enExample)
SG (1) SG183699A1 (enExample)
UA (1) UA99729C2 (enExample)
WO (1) WO2009023623A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010237302A1 (en) * 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
HUE044867T2 (hu) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (zh) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
US9409917B2 (en) * 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
WO2014091415A1 (en) * 2012-12-12 2014-06-19 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102232744B1 (ko) * 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
TWI644671B (zh) * 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
CA2918487C (en) * 2013-07-17 2021-08-03 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
MD20170011A2 (ro) 2014-08-06 2017-08-31 Pfizer Inc. Compuşi imidazopiridazinici
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
CA2962429C (en) 2014-09-29 2023-01-03 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
EP3233841A1 (en) * 2014-12-15 2017-10-25 Merck Patent GmbH Indole and azaindoles derivatives and their use in neurodegenerative diseases
JP6462493B2 (ja) 2015-05-29 2019-01-30 株式会社デンソー 進入判定装置、進入判定方法
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
JP7697934B2 (ja) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
CN116323581B (zh) * 2020-09-22 2025-05-30 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
CN119156388A (zh) * 2022-04-15 2024-12-17 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
DE2931323A1 (de) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh Neue n-aminoalkylindol-derivate und ihre salze
DE3131527A1 (de) * 1981-08-08 1983-02-24 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
TW229140B (enExample) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
DK1042287T3 (da) * 1997-12-24 2005-08-15 Aventis Pharma Gmbh Indolderivater som inhibitorer af faktor Xa
CZ20013608A3 (cs) * 1999-04-09 2002-05-15 Astrazeneca Ab Adamantanové deriváty
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
EP1310488A4 (en) * 2000-08-09 2005-08-10 Mitsubishi Pharma Corp CONCENTRATED BICYCLIC AMID COMPOUNDS AND THEIR MEDICAL USE
CN101284773A (zh) * 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
PL375149A1 (en) * 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
AU2003303217A1 (en) * 2002-12-20 2004-07-14 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TW200700387A (en) * 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
WO2007098214A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors

Also Published As

Publication number Publication date
EA020332B1 (ru) 2014-10-30
CA2691512A1 (en) 2009-02-19
JP2015110566A (ja) 2015-06-18
AU2008286946A1 (en) 2009-02-19
EA200971085A1 (ru) 2010-06-30
EP2185560A1 (en) 2010-05-19
WO2009023623A1 (en) 2009-02-19
UA99729C2 (en) 2012-09-25
IL202550A0 (en) 2010-06-30
CN101778850A (zh) 2010-07-14
AU2008286946B2 (en) 2013-11-21
KR20100066422A (ko) 2010-06-17
CO6251319A2 (es) 2011-02-21
BRPI0812594A2 (pt) 2015-06-23
EP2185560A4 (en) 2011-10-05
JP2010535816A (ja) 2010-11-25
SG183699A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
NZ582056A (en) Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
NL1026958C2 (nl) Aryl- of heteroarylamideverbindingen.
NL1028947C2 (nl) Gesubstitueerde methylaryl- of heteroarylamideverbindingen.
CA2645257C (en) Sulfonyl benzimidazole derivatives
US10005731B2 (en) Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases
KR101507717B1 (ko) Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논
SK282721B6 (sk) Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
CN101550114A (zh) 具有cb1拮抗、激动或部分激动活性的噻唑衍生物
NZ573832A (en) N-(4-{ 2-[4-aryl-piperazin-1-yl]ethyl} cyclohexyl)-acetamide derivatives for the treatment of neuropsychiatric disorders
NO20054206L (no) Bifenylderivater
WO2000075113A1 (en) Novel heterocyclic carboxamide derivatives
CA2919948A1 (en) Novel quinazolinones as bromodomain inhibitors
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
ATE486842T1 (de) Substituierte amide
JP2008537741A5 (enExample)
JP2005526798A (ja) 疼痛を治療するためのｖｒ−１受容体修飾因子としてのヘテロ芳香族尿素誘導体
JP5485391B2 (ja) Ｐ２ｘ７調節薬としてのジヒドロピリミドンアミド類
JP2010507664A (ja) ベンズイミダゾール化合物
WO2008130616A3 (en) Diaryl morpholines as cb1 modulators
JP2016528274A5 (enExample)
NO20082919L (no) Heteroringsubstituerte 3-alkylazetidinderivater
JP2011519845A5 (enExample)
JP2015522657A (ja) ウレア化合物および酵素阻害剤としてのそれらの使用
NZ595797A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
TWI360540B (en) Tetrahydroisoquinolylsulphonamide derivatives, the

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2015 BY SPRUSON + FERGUSON

Effective date: 20130103

LAPS Patent lapsed